<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>12(1)</volume><submitter>Kapp FG</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Non-small cell lung cancer (NSCLC) is one of the most frequent malignancies and has a high mortality rate due to late detection and lack of efficient treatments. Identifying novel drug targets for this indication may open the way for new treatment strategies. Comparison of gene expression profiles of NSCLC and normal adjacent tissue (NAT) allowed to determine that 5-alpha-reductase type I (SRD5A1) was up-regulated in NSCLC compared to NAT. This raised the question whether SRD5A1 was involved in sustained proliferation and survival of NSCLC.&lt;h4>Methods&lt;/h4>siRNA-mediated silencing of SRD5A1 was performed in A549 and NCI-H460 lung cancer cell lines in order to determine the impact on proliferation, on distribution during the different phases of the cell cycle, and on apopt</pubmed_abstract><journal>Cancer cell international</journal><pagination>1</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC3269976</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>5-alpha-reductase type I (SRD5A1) is up-regulated in non-small cell lung cancer but does not impact proliferation, cell cycle distribution or apoptosis.</pubmed_title><pmcid>PMC3269976</pmcid><pubmed_authors>Dolken G</pubmed_authors><pubmed_authors>Haendler B</pubmed_authors><pubmed_authors>Kapp FG</pubmed_authors><pubmed_authors>Kiefer T</pubmed_authors><pubmed_authors>Sommer A</pubmed_authors></additional><is_claimable>false</is_claimable><name>5-alpha-reductase type I (SRD5A1) is up-regulated in non-small cell lung cancer but does not impact proliferation, cell cycle distribution or apoptosis.</name><description>&lt;h4>Background&lt;/h4>Non-small cell lung cancer (NSCLC) is one of the most frequent malignancies and has a high mortality rate due to late detection and lack of efficient treatments. Identifying novel drug targets for this indication may open the way for new treatment strategies. Comparison of gene expression profiles of NSCLC and normal adjacent tissue (NAT) allowed to determine that 5-alpha-reductase type I (SRD5A1) was up-regulated in NSCLC compared to NAT. This raised the question whether SRD5A1 was involved in sustained proliferation and survival of NSCLC.&lt;h4>Methods&lt;/h4>siRNA-mediated silencing of SRD5A1 was performed in A549 and NCI-H460 lung cancer cell lines in order to determine the impact on proliferation, on distribution during the different phases of the cell cycle, and on apopt</description><dates><release>2012-01-01T00:00:00Z</release><publication>2012 Jan</publication><modification>2026-04-08T03:19:17.394Z</modification><creation>2019-03-27T00:48:38Z</creation></dates><accession>S-EPMC3269976</accession><cross_references><pubmed>22257483</pubmed><doi>10.1186/1475-2867-12-1</doi></cross_references></HashMap>